Cleo Diagnostics Ltd (ASX:COV)
Australia · Delayed Price · Currency is AUD 0.3250
+0.0100 (3.17%)
At close: Sep 17, 2026
Cleo Diagnostics Revenue
In the fiscal year ending June 30, 2026, Cleo Diagnostics had annual revenue of 1.72M AUD with 103.17% growth.
Revenue
1.72M
Revenue Growth
+103.17%
P/S Ratio
25.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
44.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 1.72M | 871.98K | 103.17% |
| Jun 30, 2025 | 845.17K | 634.36K | 300.91% |
| Jun 30, 2024 | 210.81K | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Saluda Medical | 130.35M |
| SomnoMed | 114.53M |
| Compumedics | 61.88M |
| Nova Eye Medical | 34.87M |
| Cyclopharm | 34.42M |
| CleanSpace Holdings | 19.82M |
| Lumos Diagnostics Holdings | 19.07M |
| OncoSil Medical | 5.09M |